Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
1
-
Shares change
-
-52.8K
-
Total reported value, excl. options
-
$2.54K
-
Value change
-
-$4.15M
-
Number of sells
-
-3
-
Price
-
$2,540.00
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q3 2025
4 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q3 2025.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1 shares
of 108M outstanding shares and own 0% of the company stock.
Largest 4 shareholders include HUNTINGTON NATIONAL BANK (1 shares), DekaBank Deutsche Girozentrale (0 shares), OSAIC HOLDINGS, INC. (0 shares), and Kestra Investment Management, LLC (0 shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.